KDR and osteosarcoma: miR-134 was a tumor suppressor by targeting VEGFA (vascular endothelial growth factor)/VEGFR1 (vascular endothelial growth factor receptor 2) signaling to attenuate the progression and angiogenesis in osteosarcoma [35].